Proposed removal of risk statements about cardiovascular diseases, breast cancer, and probable dementia from the boxed warnings, as well as other proposed safety-related labeling changes, to clarify the benefit/risk considerations for these drugs.
Similar Posts
Anesthetic and Analgesic Drug Products Advisory Committee Roster
This page contains the AADPAC roster, which lists the current members and the current number of vacancies for the committee.BAKKAVOR USA Issues Allergy Alert for 16-Ounce Meal Simple Red Lentil Dal Soup Due to Undeclared Milk
Charlotte, NC (December 9, 2025) – Bakkavor USA of Charlotte, North Carolina, is initiating a recall of 16-ounce Meal Simple brand Red Lentil Dal Soup, BEST BY 1/11/2026 as it contains undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threateniEarly Alert: Automated Impella Controller Purge Retainer Fixation Issue from Abiomed
FDA is announcing an Early Alert for Abiomed’s Automated Impella Controller due to Purge Pressure IssuesWalgreen Company – 662158 – 12/19/2025
Failure to Register and ListCompounding Quality Center of Excellence | Instructor-Led Trainings
The Compounding Quality Center of Excellence’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.Fantasy Aphrodisiac Chocolate may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Fantasy Aphrodisiac Chocolate, a product promoted and sold for sexual enhancement on various websites, including gearisle.com, and possibly in some retail stores.